Genetic Testing (PGT/PGD) in Rajasthan: A Complete Clinical Guide for Couples Seeking Healthy Pregnancies

Preimplantation Genetic Testing (PGT) is an umbrella term for laboratory procedures that examine the genetic material of embryos created through IVF before they are transferred to the uterus. It has three main subtypes: PGT-A (formerly PGS) screens for aneuploidy — abnormal chromosome numbers such as Down syndrome (trisomy 21) or Turner syndrome; PGT-M (formerly PGD) tests for specific monogenic or single-gene disorders such as thalassemia, Duchenne muscular dystrophy, and spinal muscular atrophy; and PGT-SR detects structural chromosomal rearrangements in couples where one partner carries a balanced translocation.

The process begins after a standard IVF cycle produces blastocyst-stage embryos on day 5 or 6. An embryologist performs a trophectoderm biopsy — carefully removing 5–8 cells from the outer layer of the embryo that would form the placenta, leaving the inner cell mass intact. These cells are then analysed using next-generation sequencing (NGS) or array comparative genomic hybridisation (aCGH). Only embryos confirmed as chromosomally normal or free of the targeted genetic mutation are transferred, significantly reducing the risk of miscarriage, failed implantation, or the birth of a child with a serious genetic condition. HomeIVF coordinates this entire pathway for Rajasthan-based couples.

Genetic testing is not universally recommended for every IVF patient, but it is strongly indicated for specific clinical profiles. Women aged 37 and above face a statistically higher risk of producing aneuploid embryos due to age-related decline in egg quality — making PGT-A particularly valuable for patients in this group seeking IVF in Jaipur or Kota. Couples who have experienced two or more unexplained miscarriages should also discuss PGT-A with their care team, as chromosomal abnormalities in embryos account for a significant proportion of first-trimester losses.

PGT-M is specifically indicated when one or both partners are confirmed carriers of a serious hereditary condition. Given Rajasthan's significant population of communities with documented carrier rates for beta-thalassemia, sickle cell anaemia, and certain metabolic disorders, genetic counselling followed by PGT-M can be a profoundly preventive intervention. Additionally, couples where one partner carries a balanced chromosomal translocation — often discovered only after repeated IVF failures or miscarriages — are strong candidates for PGT-SR. A prior child born with a chromosomal or genetic condition, or a family history of X-linked disorders, also warrants specialist evaluation for preimplantation genetic testing.

Many couples arrive at genetic testing only after experiencing unexplained infertility or repeated pregnancy losses — a painful and often costly journey. There are, however, clinical signals that should prompt earlier referral for genetic evaluation. Recurrent implantation failure — defined as failure of three or more good-quality embryo transfers — is one of the clearest indicators. Similarly, a history of two or more clinical miscarriages, particularly in the first trimester, warrants chromosomal karyotyping of both partners before the next IVF cycle.

On the single-gene disorder front, couples who have undergone carrier screening and discovered they are both carriers of an autosomal recessive condition — such as thalassemia major or cystic fibrosis — face a 25% risk of an affected pregnancy with each conception. In Udaipur and surrounding areas, consanguineous marriages, though culturally contextual, are associated with a higher likelihood of both partners carrying the same recessive gene variant. Severe male factor infertility with very low sperm counts may also be linked to Y-chromosome microdeletions, detectable through specialised genetic testing. HomeIVF's intake process includes a structured genetic risk questionnaire to flag these indicators early.

Before proceeding to PGT, a thorough diagnostic workup ensures the right type of genetic testing is selected and that the IVF cycle is appropriately planned. Both partners typically undergo peripheral blood karyotyping to identify any chromosomal rearrangements. If PGT-M is planned, the specific genetic mutation must be identified and confirmed through targeted gene sequencing — a process sometimes requiring family member samples for accurate probe design, particularly for rare variants.

For female partners, ovarian reserve assessment using antral follicle count (AFC) and day-2 or day-3 serum AMH, FSH, and LH levels is essential, as PGT requires sufficient embryos to increase the probability of having at least one euploid embryo for transfer. A saline infusion sonogram or hysteroscopy may be recommended to rule out uterine structural abnormalities that could independently impair implantation. Male partners undergo a semen analysis and, when indicated, sperm DNA fragmentation testing. Couples in Jodhpur and other tier-2 cities in Rajasthan can now have most of this workup coordinated through HomeIVF's partner laboratory network, reducing the need for multiple clinical visits to a distant city.

HomeIVF delivers a structured, senior-specialist-supervised PGT pathway that integrates remote consultations, locally coordinated diagnostics, and centralised genetic laboratory analysis. The journey begins with a video consultation with a HomeIVF fertility specialist who reviews the couple's medical history, previous cycle data, and carrier screening results to determine whether PGT-A, PGT-M, or PGT-SR is most appropriate.

Once the IVF stimulation cycle begins, follicle monitoring is managed through HomeIVF's home-visit nursing team or coordinated with a partner clinic in the patient's city — whether that is Jaipur, Udaipur, or Kota. Egg retrieval, fertilisation, and embryo culture to blastocyst stage are performed at a partner-empanelled laboratory. The trophectoderm biopsy is conducted by a trained embryologist, and biopsied samples are dispatched to an accredited genetics laboratory for NGS-based analysis. Results are reviewed by the HomeIVF Medical Board, and a comprehensive report is discussed with the couple during a follow-up consultation. Only euploid or mutation-free embryos are shortlisted for frozen embryo transfer in a subsequent cycle, maximising the safety and efficiency of every transfer attempt.

One of the most common concerns for couples seeking PGT/PGD in Rajasthan is cost and the fear that advanced genetic testing is financially inaccessible outside of metropolitan centres like Delhi or Mumbai. HomeIVF offers IVF packages starting from ₹1.5 lakh, and PGT add-ons are priced transparently with no hidden laboratory fees — a breakdown is provided during the initial consultation so couples can plan finances realistically.

In terms of timelines, couples should plan for approximately 6–10 weeks from the start of the stimulation cycle to embryo transfer when PGT is included. This accounts for 10–14 days of stimulation, egg retrieval and fertilisation, 5–6 days of embryo culture to blastocyst, the trophectoderm biopsy, and 10–14 working days for laboratory results before scheduling the frozen embryo transfer in a subsequent natural or medicated cycle. For couples in smaller cities across Rajasthan, HomeIVF eliminates the need to relocate by coordinating trigger injections, monitoring scans, and post-transfer luteal support through locally available resources, with all clinical decisions overseen remotely by senior fertility specialists.

Rajasthan is a geographically large state where access to tertiary fertility centres is concentrated primarily in Jaipur, with limited specialist infrastructure in cities like Bharatpur, Bikaner, Sikar, or Chittorgarh. This creates a significant barrier for couples who need regular monitoring during an IVF-PGT cycle — monitoring that traditionally requires visits every 2–3 days during ovarian stimulation. HomeIVF's home-monitoring model directly addresses this gap by deploying trained fertility nurses for home blood draws and coordinating follicle tracking scans with local diagnostic centres.

All monitoring data is reviewed in real time by the HomeIVF Medical Board, ensuring that dosing adjustments and trigger timing decisions reflect senior specialist oversight rather than localized general practitioner judgement. Medication delivery, injection training, and progesterone supplementation management are all handled within the HomeIVF ecosystem, meaning a couple in Jodhpur or Udaipur receives the same quality of cycle management as a patient attending a top-tier clinic in a metro city. Post-transfer care, including beta-hCG testing and early pregnancy ultrasound, is similarly coordinated through the home-care model, reducing both travel costs and the psychological burden of long-distance fertility treatment.

Despite the clinical value of PGT/PGD, several barriers prevent Rajasthan couples from accessing this technology. First, awareness remains limited — many couples and even some local gynaecologists are unfamiliar with PGT-M's role in preventing heritable conditions, particularly in communities with known carrier burdens. HomeIVF addresses this through structured genetic counselling sessions, available in Hindi, that clearly explain who benefits from testing and what the results mean for family planning decisions.

Second, the absence of accredited preimplantation genetics laboratories within Rajasthan itself means samples must be transported to centralised NGS facilities — a logistics challenge HomeIVF has pre-solved through established cold-chain biopsy transport partnerships. Third, social stigma around infertility and genetic conditions can deter couples from seeking testing, particularly in conservative communities. HomeIVF's digital-first, privacy-protected consultation model allows couples to explore genetic testing options from the discretion of their homes in Jaipur, Kota, or rural Rajasthan without navigating the social visibility of a physical clinic visit. Together, these solutions make PGT/PGD genuinely accessible, not just theoretically available.